Navigation Links
Study Casts Doubt on Costly Treatment for Leg Clots
Date:7/22/2014

By
HealthDay Reporter

TUESDAY, July 22, 2014 (HealthDay News) -- Two treatments that break up blood clots deep in the veins of the legs appear no different in terms of death risk. However, one results in a greater risk of bleeding and average hospitalization bills that are three times the cost of the other treatment, a new study finds.

The standard treatment for these clots -- known as deep vein thrombosis (DVT) -- is blood-thinning medications and compression stockings. The other, more expensive treatment delivers medication directly to the clot to dissolve it. This procedure, called catheter-directed thrombolysis, has increased in use in recent years despite inconclusive research as to its safety, the study authors said.

"DVT is a very common disease that occurs in about one in 1,000 people per year," said lead researcher Dr. Riyaz Bashir, an associate professor of medicine at Temple University School of Medicine in Philadelphia.

"This condition is responsible for more than 600,000 hospitalizations each year in the United States, and approximately 6 percent of these patients will die within one month of the diagnosis," he said.

About 20 percent to 50 percent of people with deep vein thrombosis develop a serious complication called post-thrombotic syndrome, despite conventional treatment with blood-thinning medications and compression stockings, Bashir said. The patients experience chronic leg pains, swelling, skin discoloration and ulcers.

"Many of these people lose their jobs because of the disability it causes," Bashir added.

Dr. Gregg Fonarow, a professor of cardiology at the University of California, Los Angeles, said several small studies have suggested that use of catheter-directed thrombolysis may lead to a decrease in risk for post-thrombotic syndrome.

"However, none of these studies have been definitive," Fonarow said. "Guideline recommendations regarding catheter-delivered thrombolysis are mixed, and use in clinical practice is modest and varies substantially by hospital," he added.

For the new study, published online July 21 in JAMA Internal Medicine, Bashir's team collected data on more than 90,600 patients hospitalized for deep vein thrombosis from 2005 through 2010.

About 4 percent of these patients underwent catheter-directed thrombolysis and also received blood-thinning drugs, the researchers found.

Over the study period, use of the catheter procedure more than doubled -- increasing from a little more than 2 percent in 2005 to nearly 6 percent in 2010, the study authors said.

Catheter-directed thrombolysis is an invasive treatment, and it's a potentially expensive one: $85,094 for the average hospital stay compared to $28,164 for patients given the anti-clotting medication and compression stockings, the researchers said.

Bashir's group found no significant difference in deaths between the treatments -- 1.2 percent for catheter-directed thrombolysis versus 0.9 percent for blood-thinning drugs.

But more complications were seen among patients who had catheter-directed thrombolysis. These included the need for blood transfusions, clots traveling to the lungs and bleeding in the brain. There was also a greater need for so-called vena cava filter placement -- placement of a filter to trap blood clots in the large vein that brings blood to the heart.

Patients who underwent catheter-directed thrombolysis also stayed in the hospital longer than those treated with anti-clotting drugs -- 7.2 days versus 5 days, according to the study.

Doctors should offer both treatment options to patients and explain the increased bleeding risks associated with catheter-directed thrombolysis on the one hand, and the increased risk of post-thrombotic syndrome with conventional treatment, on the other, he said.

"We believe this study data should foster shared decision making among the patients and their treating physician, which is very rarely done at present," Bashir said.

Fonarow said that a "randomized trial" that pits catheter-delivered thrombolysis against standard treatment is needed to see if catheter-delivered thrombolysis is better or not.

"While awaiting further evidence, catheter-delivered thrombolysis may be considered in patients with DVT who are at low risk for bleeding," Fonarow said.

More information

To learn more about deep vein thrombosis, visit the U.S. National Heart, Lung, and Blood Institute.

SOURCES: Riyaz Bashir, M.D., associate professor, medicine, Temple University School of Medicine, Philadelphia, Penn.; Gregg Fonarow, M.D., professor, cardiology, University of California, Los Angeles; July 21, 2014, JAMA Internal Medicine, online


'/>"/>
Copyright©2014 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Casts Doubt on Costly Treatment for Leg Clots
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and fastest ... to open a flagship location in Covington, LA at 401 N. U.S. Highway 190, ... next to Office Depot in the Holiday Square shopping center. Its location allows it ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will ... the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey ... Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United States, ... In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the ... have extremely low property-tax rates, which contributes to the relatively lower cost of ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
(Date:9/12/2017)... Sept. 12, 2017   EcoVadis , the leading platform for environmental, ... first annual edition of its Global CSR Risk and Performance Index. The ... EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points across ... ... ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., ... Solutions (VLMS), is pleased to announce the appointment ... member of its Board of Directors and Chairman ... VLMS enables life science companies to manage their ... use of paper in this process. Furthermore, ValGenesis ...
Breaking Medicine Technology: